We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
MERAIODE: A Phase II Redifferentiation Trial with Trametinib and <sup>131</sup>I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer.
- Authors
Leboulleux, Sophie; Benisvy, Daniele; Taieb, David; Attard, Marie; Bournaud, Claire; Terroir-Cassou-Mounat, Marie; Lacroix, Ludovic; Anizan, Nadege; Schiazza, Aurelie; Garcia, Marie Eve; Ghuzlan, Abir Al; Lamartina, Livia; Schlumberger, Martin; Godbert, Yann; Borget, Isabelle
- Abstract
Abnormal SP 131 sp I uptake was present at baseline (dc1-WBS) in 3 out of 10 (30%) patients, on dc2-WBS in 4 out of 9 (44.4%) patients, and on the post-treatment WBS in 6 out of 10 (60%) patients. Subsequently, the response rate at 6 months was only 20% and the response rate was anecdotal in patients who received a second course of trametinib SP 131 sp I. The 12- and the 24-month-PFS rates were also low, being 60% and 40%, respectively, in patients who had an RECIST progression within 18 months before inclusion. Tumor response was assessed according to RECIST version 1.1 at 1, 3, 6, 12, and 18 months after trametinib initiation or until tumor progression.[7] Patients with a partial response assessed by the local investigator at 6 or 12 months could undergo a second course of trametinib SP 131 sp I (5500 MBq-150 mCi after rhTSH).
- Subjects
THYROID cancer; IODINE isotopes; NUCLEOTIDE sequencing; ANAPLASTIC thyroid cancer
- Publication
Thyroid, 2023, Vol 33, Issue 9, p1124
- ISSN
1050-7256
- Publication type
Article
- DOI
10.1089/thy.2023.0240